A $1.2 million MDA grant will help move an experimental cell-penetrating treatment for myotubular myopathy toward human testing
posted on May 30, 2013 - 5:00am
The Muscular Dystrophy Association has awarded $1,195,762 over two years to biotechnology company Valerion Therapeutics (formerly 4s3 Bioscience) for development of a treatment for myotubular myopathy (MTM).
An increasingly popular trend in funding research projects is “venture philanthropy,” which applies effective business principles and practices to nonprofit goals.
Now, MDA has put this model to work for its research program by creating a new nonprofit spin-off, MDA Venture Philanthropy (MVP), that seeks to overcome barriers and speed the development of drugs for the diseases in MDA’s program.